CN113768674A

CN113768674A - a vascular stent

Info

Publication number: CN113768674A
Application number: CN202011591161.4A
Authority: CN
Inventors: 卓盈; 傅宜方; 刘振民
Original assignee: Guangzhou Savetech Co ltd
Current assignee: Guangzhou Savetech Co ltd
Priority date: 2020-12-29
Filing date: 2020-12-29
Publication date: 2021-12-10

Abstract

The invention discloses a blood vessel support which is characterized in that the support has a self-cleaning function, secondary embolism and stenosis are not easy to form around the support, the hemodynamic direction can be changed, the intravascular sedimentation is slowed down, and the arteriosclerosis speed can be delayed. The invention can be used for coronary artery stenotic embolism and after coronary artery rehabilitation, and the risk of secondary operation is not easy to cause after other parts of arterial stenotic embolism and coronary artery rehabilitation. The invention also has the characteristics of low cost, remarkable economic benefit and the like.

Description

Blood vessel support

Technical Field

The invention belongs to the field of medical treatment and relates to an apparatus for heart rehabilitation and improvement of arterial blood flow supply.

Background

Whether peripheral vascular diseases or cardiovascular and cerebrovascular diseases, the treatment modes mainly comprise three main groups, namely traditional medicine conservation treatment, traditional surgical treatment and interventional technology treatment under fluoroscopy. The medical treatment is usually suitable for the conditions of light illness, bad condition and incapability of tolerating the operation, has relatively long treatment period, slow effect and certain side effect, and even generates drug dependence. Trauma from traditional surgical procedures can cause significant harm to the patient's body. Moreover, when the population suffering from cardiovascular diseases is mainly the elderly, the postoperative recovery is slower than that of young people. Therefore, interventional therapy is a minimally invasive treatment method with small surgical trauma and good curative effect, and is undoubtedly the first choice treatment method for most arterial diseases. In the interventional operation process, under the image monitoring, a guide wire enters through an artery with a smaller internal pipe diameter of a human body to reach a target blood vessel, the blood vessel is firstly visualized under an X-ray by injecting a contrast medium, and the diameter of the blood vessel is measured so as to select a blood vessel stent and a saccule with proper sizes.

Among them, the vascular stent has been developed from the first generation to the third generation. The first generation of blood vessel stent is naked stent, after being implanted into blood vessel, can temporarily solve the problem of blood vessel stenosis, but easily form thrombus after a long time, cause blood vessel restenosis, therefore, the second generation of blood vessel stent appears. The second generation of blood vessel stent is a drug coating stent, the anti-coagulation drug is slowly released through a drug layer to delay the reformation of thrombus, the rate of the reformation of thrombus can be reduced by 80 percent, the drug coating stent once becomes a major invention in medical history, the drug coating stent brings good news to cardiovascular patients, but the production technology is monopolized by two families of strong production and Boston. In fact, the drug coating is not always possible, and when the drug on the stent is released, thrombus is formed again, and the blood vessel is embolized again. Therefore, the research of the third generation of the vascular stent is started. On one hand, people ask biotechnology to coat stem cells on the surface of a stent, namely the cell coating stent, and a vascular membrane is formed on the stent, but the risk of restenosis still exists, so that hemodynamics research is carried out, the vascular stent has a self-cleaning function, and the vascular stent is known to be like a river-blocking dam, and does not exist in front of the dam, and silting is easily formed behind the dam to cause restenosis.

Disclosure of Invention

We have thus achieved the object of the invention by means of a large number of trial and error experiments.

Further explanation is as follows:

a vascular stent is characterized in that two flow guide devices are arranged on a two-stage annular stent to cause blood liquid to rotate, so that the stent and flow guide strips are continuously washed, and the phenomenon of 'behind-dam siltation' does not exist.

The intravascular stent is characterized in that both ends of the diversion strips adopt spherical structures, so that the risk of hanging and breaking blood vessels is avoided.

The intravascular stent is characterized in that a foldable structure is adopted, and when X-rays are guided to a narrow placing part, the folding and pulling lines are released, and the intravascular stent is automatically propped open.

The vascular stent is characterized in that a biocompatible material is adopted, so that 'foreign inflammation' is not easy to cause, and complications are caused.

The vascular stent is characterized in that a slow release technology is adopted, and anticoagulant drugs are continuously released on the surface of the vascular stent to prevent thrombosis. Preventing restenosis.

The foldable structure is characterized in that the transverse folding is reduced, the longitudinal size is unchanged, and the operation is convenient to implement.

The biocompatible material comprises rigid materials such as alloy, ceramic and polycarbonate plastic and compatible coating materials, and comprises starch polymer, chitin, polylactic acid (PLA) and Polyethylene glycol (PEG).

The anticoagulant drugs comprise discovered drugs and drugs discovered in the future, and the drugs are warfarin, heparin sodium, small molecular dextran and snake blood anticoagulant enzyme.

Drawings

Fig. 1 is a schematic view of a vascular stent, wherein 1 is a front support ring, 2 is a folding groove buckle, 3 is a folding groove, 4 is a spinning disk, 5 lower support ring folding grooves, 6 is a rear support ring, and 7 is a lower support ring folding groove.

Fig. 2 is an isometric view of a vascular stent reflecting the overall appearance of the vascular stent.

When blood flows enter from the end and act on the blood vessel arm, the rotational flow is generated under the influence of the rotational flow sheet, so that solid particles such as low-density protein particles and blood platelets which are easy to deposit cannot stay at the rotational flow sheet, the blood fluid is utilized to automatically clean the bracket, and the risk that the bracket in the previous generations is easy to be embolized is overcome. The technical solution of the present invention is further illustrated by the following examples.

Detailed Description

Example one

We placed the scaffolds prepared according to the present invention and the second generation scaffolds in 4 canine cardiac vessels, respectively. And the positions are exchanged, a contrast test is carried out for 720 days, the stent and the blood vessel at the stent part are taken out, and the change of the surface of the third generation stent and the change of the periphery of the blood vessel are obviously better than those of the second generation stent observed under a microscope.

Example two

After the beagle dogs placed with the second generation and the third generation vascular stents are raised for half a year, one year, two years and five years, the positions of the stents are dissected, the risk of the third generation stents occurring the secondary plugging match is found to be smaller, although the positions of the stents placed are proliferated, the third generation stents generate rotational flow grooves, and the risk of the secondary plugging and the coronary atherosclerotic lesion is reduced.

What has been described above are merely some embodiments of the present invention. It will be apparent to those skilled in the art that various changes and modifications can be made without departing from the inventive concept thereof, and these changes and modifications can be made without departing from the spirit and scope of the invention.

Claims

1. A vascular stent is characterized in that two guide devices are configured on the two-stage annular stent, which causes the blood liquid to rotate, and continuously flushes the stent and the guide strip.

2 . The vascular stent according to claim 1 , wherein both ends of the guide strip adopt spherical structures. 3 .

3. The vascular stent according to claim 1 is characterized in that it adopts a foldable structure.

4. The vascular stent of claim 1 is characterized in that a biocompatible material is used.

5. The vascular stent according to claim 1 is characterized in that a sustained-release technology is adopted, and anticoagulant drugs are continuously released on the surface.

6. The foldable structure as claimed in claim 3 belongs to the aspect of being reduced in size when folded in the transverse direction, and the longitudinal dimension is unchanged.

7. The biocompatible material according to claim 4 includes rigid materials such as alloys, ceramics, polycarbonate plastics, and compatible coating materials, the latter including starch polymer, chitin, polylactic acid (PLA) , Polyethylene glycol (Polyethylene glycol, PEG).

8. The anticoagulant drugs according to claim 5, including those already discovered and those discovered in the future, are warfarin, heparin sodium, small molecule dextran, and snake blood anticoagulase.